Canaccord Genuity Trims PT on Anacor Pharmaceuticals (ANAC), Keeps Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Deutsche Says Anacor (ANAC) Tavaborole Numbers are Solid, Hinges on 2nd Phase 3 Results
January 29, 2013 1:12 PM ESTAnacor Pharmaceuticals (Nasdaq: ANAC) is getting slammed amid new tavaborole phase 3 data, the Company's key pipeline candidate for the treatment of onychomycosis (nail fungus).
Deutsche Bank issued comments on the results. The firm said, "By comparison, Penlac the first and only approved topical treatment for this indication achieved peak sales of $300M on a worldwide basis ($120M in the US) prior to... More
Anacor Pharma (ANAC) Reports Positive P-3 Data on Tavaborole for Onychomycosis
January 29, 2013 7:10 AM ESTAnacor Pharmaceuticals (NASDAQ: ANAC) today announced positive preliminary results from the first of two Phase 3 trials of tavaborole, its topical anti-fungal for onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States. Tavaborole achieved a high... More
